Hyperinsulinemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major hyperinsulinemia markets reached a value of US$ 70.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 114.9 Million by 2034, exhibiting a growth rate (CAGR) of 4.61% during 2024-2034.
The hyperinsulinemia market has been comprehensively analyzed in IMARC's new report titled "Hyperinsulinemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hyperinsulinemia refers to a condition characterized by abnormally high levels of insulin in the bloodstream. It typically does not manifest with specific symptoms on its own but is often associated with underlying disorders like insulin resistance, obesity, metabolic syndrome, etc. Individuals suffering from hyperinsulinemia may experience various indications, such as persistent hunger, frequent cravings for carbohydrates, difficulty losing weight, increased abdominal fat deposition, high blood pressure, elevated triglyceride levels, low HDL cholesterol levels, impaired glucose tolerance, etc. The diagnosis of the ailment typically involves a combination of clinical assessment, medical history review, and laboratory tests. Fasting insulin levels are commonly measured to determine baseline insulin concentrations, with elevated levels indicating hyperinsulinemia. An oral glucose tolerance test (OGTT) may also be performed, involving the measurement of glucose and insulin levels at various intervals after consuming a glucose solution. Additionally, several diagnostic imaging techniques, such as magnetic resonance imaging (MRI) and computed tomography (CT) scans, are utilized to assess fat distribution as well as identify associated conditions. Furthermore, genetic testing may be considered in cases of suspected monogenic forms of hyperinsulinemia.
The escalating cases of insulin resistance, characterized by increased insulin production to compensate for reduced cellular response, are primarily driving the hyperinsulinemia market. Additionally, the rising prevalence of various associated risk factors, including sedentary lifestyles, excessive carbohydrate intake, chronic stress, preexisting medical conditions like polycystic ovary syndrome, genetic predisposition, hormonal imbalances, etc., is also creating a positive outlook for the market. Moreover, the widespread adoption of numerous insulin-lowering agents, such as glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by stimulating insulin secretion in response to elevated blood sugar levels, thus reducing the demand for insulin, is further bolstering the market growth. Apart from this, the inflating application of probiotics and prebiotics, since they aid in modulating the gut microbiota while alleviating insulin resistance and inflammation, is acting as another significant growth-inducing factor. Additionally, the ongoing advancements in diagnostic technologies, including the introduction of continuous glucose monitoring (CGM) systems that offer real-time monitoring of glucose levels, insulin response, and metabolic patterns, are expected to drive the hyperinsulinemia market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the hyperinsulinemia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hyperinsulinemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hyperinsulinemia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the hyperinsulinemia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the hyperinsulinemia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current hyperinsulinemia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the hyperinsulinemia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the hyperinsulinemia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the hyperinsulinemia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of hyperinsulinemia across the seven major markets?
What is the number of prevalent cases (2018-2034) of hyperinsulinemia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of hyperinsulinemia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with hyperinsulinemia across the seven major markets?
What is the size of the hyperinsulinemia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of hyperinsulinemia?
What will be the growth rate of patients across the seven major markets?
Hyperinsulinemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for hyperinsulinemia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hyperinsulinemia market?
What are the key regulatory events related to the hyperinsulinemia market?
What is the structure of clinical trial landscape by status related to the hyperinsulinemia market?
What is the structure of clinical trial landscape by phase related to the hyperinsulinemia market?
What is the structure of clinical trial landscape by route of administration related to the hyperinsulinemia market?
The hyperinsulinemia market has been comprehensively analyzed in IMARC's new report titled "Hyperinsulinemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hyperinsulinemia refers to a condition characterized by abnormally high levels of insulin in the bloodstream. It typically does not manifest with specific symptoms on its own but is often associated with underlying disorders like insulin resistance, obesity, metabolic syndrome, etc. Individuals suffering from hyperinsulinemia may experience various indications, such as persistent hunger, frequent cravings for carbohydrates, difficulty losing weight, increased abdominal fat deposition, high blood pressure, elevated triglyceride levels, low HDL cholesterol levels, impaired glucose tolerance, etc. The diagnosis of the ailment typically involves a combination of clinical assessment, medical history review, and laboratory tests. Fasting insulin levels are commonly measured to determine baseline insulin concentrations, with elevated levels indicating hyperinsulinemia. An oral glucose tolerance test (OGTT) may also be performed, involving the measurement of glucose and insulin levels at various intervals after consuming a glucose solution. Additionally, several diagnostic imaging techniques, such as magnetic resonance imaging (MRI) and computed tomography (CT) scans, are utilized to assess fat distribution as well as identify associated conditions. Furthermore, genetic testing may be considered in cases of suspected monogenic forms of hyperinsulinemia.
The escalating cases of insulin resistance, characterized by increased insulin production to compensate for reduced cellular response, are primarily driving the hyperinsulinemia market. Additionally, the rising prevalence of various associated risk factors, including sedentary lifestyles, excessive carbohydrate intake, chronic stress, preexisting medical conditions like polycystic ovary syndrome, genetic predisposition, hormonal imbalances, etc., is also creating a positive outlook for the market. Moreover, the widespread adoption of numerous insulin-lowering agents, such as glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by stimulating insulin secretion in response to elevated blood sugar levels, thus reducing the demand for insulin, is further bolstering the market growth. Apart from this, the inflating application of probiotics and prebiotics, since they aid in modulating the gut microbiota while alleviating insulin resistance and inflammation, is acting as another significant growth-inducing factor. Additionally, the ongoing advancements in diagnostic technologies, including the introduction of continuous glucose monitoring (CGM) systems that offer real-time monitoring of glucose levels, insulin response, and metabolic patterns, are expected to drive the hyperinsulinemia market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the hyperinsulinemia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hyperinsulinemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hyperinsulinemia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the hyperinsulinemia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the hyperinsulinemia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current hyperinsulinemia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the hyperinsulinemia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the hyperinsulinemia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the hyperinsulinemia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of hyperinsulinemia across the seven major markets?
What is the number of prevalent cases (2018-2034) of hyperinsulinemia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of hyperinsulinemia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with hyperinsulinemia across the seven major markets?
What is the size of the hyperinsulinemia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of hyperinsulinemia?
What will be the growth rate of patients across the seven major markets?
Hyperinsulinemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for hyperinsulinemia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hyperinsulinemia market?
What are the key regulatory events related to the hyperinsulinemia market?
What is the structure of clinical trial landscape by status related to the hyperinsulinemia market?
What is the structure of clinical trial landscape by phase related to the hyperinsulinemia market?
What is the structure of clinical trial landscape by route of administration related to the hyperinsulinemia market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HYPERINSULINEMIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 HYPERINSULINEMIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HYPERINSULINEMIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 HYPERINSULINEMIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HYPERINSULINEMIA - UNMET NEEDS
10 HYPERINSULINEMIA - KEY ENDPOINTS OF TREATMENT
11 HYPERINSULINEMIA - MARKETED PRODUCTS
11.1 List of Hyperinsulinemia Marketed Drugs Across the Top 7 Markets
11.1.1 Proglycem (Diazoxide) - Teva Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 HYPERINSULINEMIA - PIPELINE DRUGS
12.1 List of Hyperinsulinemia Pipeline Drugs Across the Top 7 Markets
12.1.1 HM15136 - Hanmi Pharmaceutical
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Dasiglucagon - Zealand Pharma
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Avexitide - Eiger BioPharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. HYPERINSULINEMIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. HYPERINSULINEMIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 HYPERINSULINEMIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Hyperinsulinemia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Hyperinsulinemia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Hyperinsulinemia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Hyperinsulinemia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Hyperinsulinemia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Hyperinsulinemia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Hyperinsulinemia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Hyperinsulinemia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Hyperinsulinemia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Hyperinsulinemia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Hyperinsulinemia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Hyperinsulinemia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Hyperinsulinemia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Hyperinsulinemia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Hyperinsulinemia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Hyperinsulinemia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Hyperinsulinemia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Hyperinsulinemia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Hyperinsulinemia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Hyperinsulinemia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Hyperinsulinemia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Hyperinsulinemia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Hyperinsulinemia - Access and Reimbursement Overview
16 HYPERINSULINEMIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 HYPERINSULINEMIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 HYPERINSULINEMIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HYPERINSULINEMIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 HYPERINSULINEMIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HYPERINSULINEMIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 HYPERINSULINEMIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HYPERINSULINEMIA - UNMET NEEDS
10 HYPERINSULINEMIA - KEY ENDPOINTS OF TREATMENT
11 HYPERINSULINEMIA - MARKETED PRODUCTS
11.1 List of Hyperinsulinemia Marketed Drugs Across the Top 7 Markets
11.1.1 Proglycem (Diazoxide) - Teva Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 HYPERINSULINEMIA - PIPELINE DRUGS
12.1 List of Hyperinsulinemia Pipeline Drugs Across the Top 7 Markets
12.1.1 HM15136 - Hanmi Pharmaceutical
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Dasiglucagon - Zealand Pharma
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Avexitide - Eiger BioPharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. HYPERINSULINEMIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. HYPERINSULINEMIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 HYPERINSULINEMIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Hyperinsulinemia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Hyperinsulinemia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Hyperinsulinemia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Hyperinsulinemia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Hyperinsulinemia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Hyperinsulinemia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Hyperinsulinemia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Hyperinsulinemia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Hyperinsulinemia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Hyperinsulinemia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Hyperinsulinemia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Hyperinsulinemia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Hyperinsulinemia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Hyperinsulinemia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Hyperinsulinemia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Hyperinsulinemia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Hyperinsulinemia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Hyperinsulinemia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Hyperinsulinemia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Hyperinsulinemia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Hyperinsulinemia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Hyperinsulinemia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Hyperinsulinemia - Access and Reimbursement Overview
16 HYPERINSULINEMIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 HYPERINSULINEMIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 HYPERINSULINEMIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
